Oric Pharmaceuticals
ORIC
65 hedge funds and large institutions have $194M invested in Oric Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 17 closing their positions.
447% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $190K
86% more capital invested
Capital invested by funds: $105M → $194M (+$89.5M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
0.18% more ownership
Funds ownership: 82.63% → 82.81% (+0.18%)
14% less funds holding
Funds holding: 76 → 65 (-11)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.2M |
| 2 |
Alkeon Capital Management
New York
|
+$987K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$823K |
| 4 |
MAM
Monaco Asset Management
Monaco
|
+$730K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$673K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.62M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.12M |
| 3 |
BlackRock
New York
|
-$812K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$504K |
| 5 |
Two Sigma Investments
New York
|
-$430K |
ORIC Hedge Fund Activity: Q4 2022 in Review
65 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q4 2022, worth a combined $194M — up 86% from $105M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ORIC and 6 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 22 added.
The largest buyer was Millennium Management, adding an estimated $1.2M. The largest seller was OrbiMed, cutting an estimated $1.62M.
- 65 institutional investors held Oric Pharmaceuticals (ORIC) as of Q4 2022, down from 76 in Q3 2022.
- Funds reported $194M of Oric Pharmaceuticals stock for Q4 2022, up 86% quarter-over-quarter.
- 6 funds opened new Oric Pharmaceuticals positions in Q4 2022 and 17 closed out, a net change of -11 holders.
- The largest Oric Pharmaceuticals buyer in Q4 2022 was Millennium Management, an estimated $1.2M added.
- The largest Oric Pharmaceuticals seller in Q4 2022 was OrbiMed, an estimated $1.62M sold.
Based on aggregated 13F filings for Q4 2022.